

1 Title: Investigating Attitudes, Motivations and Key Influencers for vaccine uptake among late  
2 adopters of COVID-19 vaccination in Africa

3 Short Title: Cross sectional survey of Attitudes to COVID-19 vaccines among Vaccine Late  
4 Adopters in Africa

5 Authors:

6 A Tariro Makadzange\*<sup>1</sup>, Charles Lau<sup>2</sup>, Janan Dietrich<sup>3</sup>, Admire Hlupeni<sup>1</sup>, Nellie Myburgh<sup>3</sup>, Patricia  
7 Gundidza<sup>1</sup>, Nyasha Elohe<sup>1</sup>, Shabir Mahdi<sup>3</sup>, Wilmot James<sup>4</sup>, Larry Stanberry<sup>4</sup>, Chiratidzo Ndhlovu<sup>1,5</sup>.

8 1 Charles River Medical Group, 155 King George Avenue, Avondale Harare

9 2 RTI International, 3040 East Cornwallis Road, Research Triangle Park

10 3 University of Witwatersrand, Faculty of Health Sciences, Johannesburg, South Africa

11 4 Vaccine Information Network, Columbia University, 533 W 218<sup>th</sup> St, New York,

12 5 Internal Medicine Unit, Faculty of Health Sciences, University of Zimbabwe, Harare, Zimbabwe

13

14 \* Corresponding author

15 Email: [tariro.makadzange@crmresearch.com](mailto:tariro.makadzange@crmresearch.com) (ATM)

16

## 17 Abstract

18

19 **Background:** The rapid development of vaccines in response to the COVID-19 pandemic has  
20 provided an effective tool for the management of COVID-19. However, in Africa there has been a  
21 poor uptake of COVID-19 vaccines with only 15% vaccine coverage compared to the WHO global  
22 target of 70%. One of the important drivers has been vaccine hesitancy, understanding late  
23 adopters of vaccination can provide insights into the attitudes, motivations and influences that  
24 can enhance vaccine uptake.

25

26 **Methods:** Between January 4 – February 11, 2022, we conducted a survey among adults  
27 presenting for their first dose of a COVID-19 vaccine almost 12-months after the vaccination  
28 program began. Vaccines were free and provided at clinics and outreach centers in Harare,  
29 Zimbabwe. The questionnaire assessed environmental and individual factors (attitudes, barriers,  
30 motivations, key influencers, and information sources) that influenced the decision to present for  
31 vaccination. Baseline socio-demographic data and responses to survey questions were  
32 summarized using descriptive statistics. Binary logistic regression models were developed to  
33 understand factors associated with vaccine confidence.

34 **Results:** 1016 adults were enrolled into the study, 508 (50%) were female, 126 (12.4%) had HIV  
35 co-infection. The median age was 30 years (IQR 22 – 39). Women were more likely to have  
36 negative views about the COVID-19 vaccine compared to men (OR 1.51 (95%CI 1.16, 1.97,  
37  $p=0.002$ ). Women compared to men and older adults ( $\geq 40$  years) compared with youth (18-25  
38 years) were more likely to have ‘major concerns’ about vaccines. Most concerns were about  
39 safety with 602 (59.3%) concerned about immediate and 520 (51.2%) about long-term health  
40 effects of vaccines. People living with HIV (PLWH) were more likely to perceive vaccines as safe

41 (OR 1.71 (95%CI: 1.07, 2.74, p=0.025), effective (1.68 (95%CI: 1.07, 2.64, p=0.026) and to trust  
42 regulatory systems for approving vaccines (OR 1.79 (95% CI: 1.11, 2.89, p=0.017) compared to  
43 those without HIV. Internet users were less likely to perceive vaccines as safe (OR 0.72 (95% CI:  
44 0.55, 0.95, p=0.021), effective (OR 0.61 (95% CI: 0.47, 0.80, p<0.001) or trust regulatory processes  
45 for approving vaccines (OR 0.64 (95% CI: 0.48, 0.85, p=0.002) compared to non-internet users.  
46 Social influence was a key factor in the decision to be vaccinated with family members being the  
47 primary key influencers for 560 (55.2%) participants. The most important reason for receiving the  
48 COVID-19 vaccine today for 715 (70.4%) participants was the protection of individual health. The  
49 most trusted source of information regarding the vaccine was the Ministry of Health (79.7%) and  
50 the radio, television and social media were the preferred sources for obtaining this information.  
51 Social media was a more likely source for youth and those with higher levels of education.

52

53 **Conclusion:** Improving vaccine coverage will need targeted communication strategies that  
54 address negative perceptions of vaccines and associated safety and effectiveness concerns.  
55 Leveraging normative behavior as a social motivator for vaccination will be important as close  
56 social networks are key influences of vaccination. Traditional media remains important for health  
57 communication in Africa and should be strengthened to counter social media-based  
58 misinformation that drives concerns about safety and effectiveness particularly among internet  
59 users.

60

## 61 **Introduction**

62 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a devastating impact  
63 on health and socio-economic well-being for millions of people. Since the start of the pandemic  
64 there have been over 460 million cases and six million deaths(1). Vaccines are one of the most  
65 effective approaches for the public health management of many infectious diseases. In response  
66 to the SARS-CoV-2 pandemic, over 300 vaccines have gone into development across various  
67 platforms(2). Among these 35 have been approved by at least one country and 10 have been  
68 approved by the World Health Organization (WHO)(3). In addition to manufacturing and  
69 distribution, widespread vaccination acceptance will be required to achieve sufficient vaccination  
70 coverage rates(4).

71 In pre-pandemic 2019, the WHO identified vaccine hesitancy as one of the top 10 threats to  
72 human health (5).Vaccine hesitancy in Africa is poorly understood particularly for adult vaccines  
73 and within key subpopulation such as people living with HIV (PLWH)(6). Studies conducted largely  
74 prior to the availability of COVID-19 vaccines suggested vaccine acceptance rates would be high  
75 in Africa(7). However, as vaccine access improves it is increasingly becoming evident that vaccine  
76 hesitancy is a major driver of low COVID-19 vaccine coverage rates in Africa(8). Vaccine  
77 acceptance lies on a spectrum and includes early adopters of all vaccines; the vaccine hesitant  
78 who take a 'wait and see' approach and may present for vaccination at later stages of the vaccine  
79 campaign; and those that do not accept all vaccines. Very little is understood about the late  
80 adopters that take a 'wait and see' approach. These individuals are among those for whom  
81 targeted approaches are likely to have the most impact in driving up vaccine coverage rates.

82 The WHO has set a target of achieving 70% vaccine coverage globally by mid-2022(9). However,  
83 Africa currently has less than 15% vaccine coverage with vaccine hesitancy being an important  
84 driver of low coverage rates(10). One year after initiating its vaccination program, first dose

85 coverage in Zimbabwe is 45.5% and second dose coverage is 35.4% (MOHCC, Zimbabwe). Over  
86 the last several months a plateau in vaccine uptake rates has been observed making the country  
87 like many African countries unlikely to reach the WHO target (8). We conducted a survey among  
88 individuals who were presenting for their first COVID-19 vaccine at public vaccination centers in  
89 Harare, Zimbabwe. The participants were presenting for vaccination one year after initiation of  
90 the vaccination program and are late adopters who lie on the vaccine hesitancy spectrum as the  
91 ‘wait and seers’(11). The aim of this study was to measure the environmental and individual  
92 factors (attitudes, barriers, motivations, key influencers, and information sources) that influence  
93 vaccine uptake among late adopters (12).

## 94 **Materials and Methods**

### 95 **Study design**

96 Between January 4<sup>th</sup> and February 11<sup>th</sup>, 2022, we conducted a quantitative survey through face-  
97 to-face interviews.

98

### 99 **Study Sites and Sampling**

100 Eligible adults ( $\geq 18$  years) who were receiving their first dose of COVID-19 vaccines at public sites  
101 providing free vaccine services at 4 City of Harare clinics (Wilkins, Kuwadzana, Budiro, Mabvuku)  
102 including their affiliated outreach sites (Mabelreign, Avondale, and Dzivarasekwa) were  
103 consecutively enrolled into the study. All individuals receiving their first COVID-19 vaccine were  
104 eligible to participate except those who had obvious cognitive impairments or were unable to  
105 provide informed consent.

106

## 107 **Study Procedures**

108 Participants at each site who were receiving the first dose of the vaccine were informed about  
109 the study while queueing to receive the vaccine. Those that agreed and were eligible participated  
110 in the survey after receiving their vaccination. Participants were reimbursed \$5 for participating  
111 in the survey.

112

## 113 **Study Measures**

114 A comprehensive questionnaire was prepared based on a user-centered design framework (13).  
115 The questionnaire consisted of six main sections including demographics (sex, age, education,  
116 socio-economic status), attitudes and views towards COVID-19 vaccines, barriers, motivations,  
117 information sources and vaccination experience (Table 1). Age was categorized into 3 groups:  
118 ages 18-25 as youth, 26-39 years as young adults and  $\geq 40$  years as older adults. Vaccine  
119 confidence was measured through survey statements related to individual perception on safety,  
120 effectiveness of vaccines and confidence in country's regulatory approval process for vaccines  
121 (14) (Table 1). Socioeconomic status was based on an assessment of available resources –  
122 electricity, television, refrigerator, bed, battery or generator for power. High socioeconomic  
123 status was defined by owning both a battery or a generator for power and a refrigerator, low  
124 economic status was defined by neither owning a refrigerator or alternative source of power. In  
125 addition, internet usage in the last 30 days, was assessed.

126

127 **Table 1. Survey questions addressing Vaccine convenience and confidence** (Full study  
128 questionnaire included in appendix)

Question	Response options
<b>Vaccine convenience</b>	
How long did it take you to travel to this vaccination site today?	Less than 15 minutes; 15-30 minutes; 31-60 minutes; 1-2 hours; More than 2 hours; Don't know; Prefer not to answer
From the time you arrived at the vaccination site, how long did it take you to get your vaccine shot?	Less than 10 minutes; 10-20 minutes; 20-30 minutes; 30-60 minutes; More than 60 minutes; Not applicable
How easy or difficult was it to register for a vaccination appointment?	Very easy, Somewhat easy; Neither easy nor difficult; Somewhat difficult; Very difficult
How easy or difficult was it to find a vaccination site?	Very easy, Somewhat easy; Neither easy nor difficult; Somewhat difficult; Very difficult
How easy or difficult was it to get to the vaccination site?	Very easy, Somewhat easy; Neither easy nor difficult; Somewhat difficult; Very difficult
How easy or difficult was it to financially afford transportation to the vaccination site?	Very easy, Somewhat easy; Neither easy nor difficult; Somewhat difficult; Very difficult
How easy or difficult was it to find a vaccination site with convenient hours?	Very easy, Somewhat easy; Neither easy nor difficult; Somewhat difficult; Very difficult
Did you need to do any of the following in order to get vaccinated today? Please select all that apply	Arrange for childcare; Take time off from paid work; Earn less money because you weren't working; None of the above
<b>Vaccine Confidence</b>	
When the COVID-19 vaccines first became available, what was your view towards COVID-19 vaccines?	Very positive; Somewhat positive; Neutral; Somewhat negative; Very negative
It is common for people to be hesitant or unsure about getting vaccinated. Did you ever have concerns about getting the COVID-19 vaccine?	Yes, major concerns; Yes, minor concerns; No concerns
Why were you concerned about getting a COVID-19 vaccine? Please select all that apply	Whether the vaccine has been tested enough; The vaccine is still new; Effectiveness of the vaccine; Immediate side effects; Long-term health effects; Don't see need for vaccine; Other (specify); None of the above
In general, COVID-19 vaccines are safe	Strongly agree; Somewhat agree; Neutral; Somewhat disagree; Strongly disagree; Don't know; Prefer not to answer
I am confident that my country's regulation process approved the COVID-19 vaccine, only when it was shown to be safe	Strongly agree; Somewhat agree; Neutral; Somewhat disagree; Strongly disagree; Don't know; Prefer not to answer
I am confident that COVID-19 vaccines are effective in preventing the disease.	Strongly agree; Somewhat agree; Neutral; Somewhat disagree; Strongly disagree; Don't know; Prefer not to answer
<b>Motivators/Influencers and Reasons for vaccination today</b>	

Which of the following people help to convince you to get vaccinated, if any? Please select all that apply.	Spouse; Children; other family member; Healthcare worker; Religious leader; Community leader; Co-worker; Media; Other (specify); None of the above
Why did you get vaccinated today? Please select all that apply.	To protect my health; To protect health of my family; To protect health of people in community; To get back to work or school; To resume social activities; To resume travel; Because other people encouraged me to get vaccinated; Other (specify); Don't know; Prefer not to answer
What is the most important reason you got vaccinated today? Select one reason only.	To protect my health; To protect health of my family; To protect health of people in community; To get back to work or school; To resume social activities; To resume travel; Because other people encouraged me to get vaccinated; Other (specify); Don't know; Prefer not to answer
Do you agree or disagree with the following statement: I came to get vaccinated because people important to me encouraged me to get vaccinated	Strongly agree; Somewhat agree; Neutral; Somewhat disagree; Strongly disagree
Do you agree or disagree with the following statement: I came to get vaccinated because people important to me got a COVID-19 vaccine themselves?	Strongly agree; Somewhat agree; Neutral; Somewhat disagree; Strongly disagree
<b>Information Sources</b>	
In the past 30 days, who have you received information from about COVID-19? Select all that apply.	Ministry of health; Local health authorities; World Health Organization (WHO); Pharmaceutical companies producing the COVID-19 vaccines; Health scientists and researchers; Your doctor; Your local clinic; Other healthcare professionals like nurses or pharmacists; Alternative health providers (e.g., faith or traditional healer; Friends or family; Religious leaders; Other people's experience or knowledge; Other (specify); None of the above
What are your top 3 sources of trusted information about COVID-19 vaccines?	Ministry of health; Local health authorities; World Health Organization (WHO); Pharmaceutical companies producing the COVID-19 vaccines; Health scientists and researchers; Your doctor; Your local clinic; Other healthcare professionals like nurses or pharmacists; Alternative health providers (e.g., faith or traditional healer; Friends or family; Religious leaders; Other people's experience or knowledge; Other (specify); None of the above
In the past 30 days, where have you obtained information about COVID-19 vaccines? Select all that apply	Radio; Television; WhatsApp; Facebook; TikTok; Instagram; Other social media; Other (specify)

130

## 131 **Statistical analysis**

132 Data were analyzed using Stata version 13 (College Station, Texas 77845 USA). Baseline socio-  
133 demographic data and responses to survey questions were summarized using means and  
134 standard deviations (SD) for normally distributed data or medians and interquartile ranges (IQRs)  
135 for non-parametric continuous variables. Absolute numbers, proportions and percentages were  
136 used for categorical data. The chi-squared test was used to test for significance between outcome  
137 variables and demographic variables such as gender, age, education, economic status, previous  
138 personal experience with COVID-19, HIV status and internet use over the last 30 days.

139

140 Binary logistic regression models were developed to examine factors associated with ‘very  
141 negative’ and ‘somewhat negative’ views to vaccines when they were first available, as well as  
142 concerns about vaccines. The outcome variables were dichotomized (Very negative/somewhat  
143 negative or Neutral/somewhat positive/very positive; Major concerns/Minor concerns or No  
144 concerns; Strongly agree or somewhat agree/neutral/somewhat disagree/strongly disagree). The  
145 variables evaluated included demographic factors such as gender, age, education, and income (a  
146 proxy for which was defined by availability of alternate sources of energy (battery or generator),  
147 and/or refrigerator ownership), personal experience with COVID-19 – knowing someone who  
148 became severely ill or died from COVID-19, internet usage and HIV status. P-values were two-  
149 sided.

150

## 151 **Ethics Approvals**

152 The protocol, consent forms and recruitment materials were reviewed and approved by the  
153 Medical Research Council of Zimbabwe, Joint Research Ethics Committee (JREC) of Parirenyatwa

154 Hospital, the University of Zimbabwe, and Harare City Health Departments prior to initiation of  
155 the study. All amendments to the protocol, consent forms and/or recruitment materials were  
156 approved by the institutional review boards before they were implemented. All participants  
157 provided written informed consent.

158

## 159 **Results**

160 A total of 1016 adults were enrolled into the study; 1013 (99.7%) received the Sinopharm vaccine  
161 and 3 (0.3%) received the Sinovac vaccine. Gender was equally distributed in the cohort with 508  
162 (50%) females, and a median age of 30 years (IQR 22-39) (Table 2). All participants were of African  
163 descent and most had attained some level of high school education. The self-reported comorbid  
164 conditions were diabetes (1.5%), cardiac disease (0.4), respiratory illnesses (2.3%), hypertension  
165 (6.6%). HIV positive status was reported by 126 (12.4%) participants. The study participants were  
166 urban residents with high levels of electricity use (87.7%), refrigerator (75.8%) and television  
167 (88%) ownership. Having a 'battery or generator for power' was reported by 240 (23.6%)  
168 participants. Ownership of these resources was used to classify participants as high, middle, or  
169 low socioeconomic status (Table 1). Among study participants 428 (42.1%) reported knowing  
170 someone who was seriously ill or died from COVID-19 disease; these were close relatives (e.g.,  
171 siblings, spouse or parents) in 30% of respondents. Internet use in the past 30 days was reported  
172 by 420 (41.4%) participants (Table2).

173

174 Table 2. Baseline cohort demographics

Characteristic	N(%)
<b>Gender (Female)</b>	508 (50%)
<b>Median age (IQR)</b>	30 (22-39)
<b>Age groups</b>	
<b>18-25 (Youth)</b>	368 (36.2%)
<b>26-39 (Young adults)</b>	409 (40.3%)
<b>≥40 (Older adults)</b>	239 (23.5%)
<b>Ethnicity (Black African)</b>	1016 (100%)
<b>Highest Level of Education</b>	
<b>No formal schooling</b>	5 (0.5%)
<b>Primary school<sup>1</sup></b>	84 (8.3%)
<b>Lower Secondary school<sup>2</sup></b>	735 (72.4%)
<b>Higher Secondary<sup>3</sup></b>	117 (11.5%)
<b>Tertiary Education</b>	74 (7.3%)
<b>Co-morbid conditions</b>	
<b>Diabetes</b>	15 (1.5%)
<b>Cardiac Disease</b>	4 (0.4%)
<b>Respiratory Illness</b>	23 (2.3%)
<b>Hypertension</b>	67 (6.6%)
<b>HIV</b>	126 (12.4%)
<b>Socioeconomic status</b>	
<b>High<sup>4</sup></b>	172 (16.9%)
<b>Middle<sup>5</sup></b>	598 (58.9%)
<b>Low<sup>6</sup></b>	246 (24.2%)
<b>Internet use</b>	
<b>In the past 30 days have you used the internet?</b>	420 (41.4%)
<b>Personal Covid experience</b>	
<b>Know someone who became seriously ill or died as a result of Covid</b>	428 (42.1%)

175 <sup>1</sup> Primary up to 7<sup>th</sup> grade

176 <sup>2</sup> High school completing up to and including Ordinary Level (GSCE or 11<sup>th</sup> Grade)

177 <sup>3</sup> Higher secondary completing Advanced Level (or 13<sup>th</sup> Grade)

178 <sup>4</sup> High socioeconomic status defined by owning a generator or battery as an alternate source of  
179 power and a refrigerator

180 <sup>5</sup> Middle socioeconomic status owned one but not the other

181 <sup>6</sup> Low socioeconomic status neither owned a refrigerator or a generator

182

183

## 184 Vaccine convenience

185 Time to travel to the vaccination site was <15 minutes for 443 (43.6%) participants. Time taken

186 to receive the shot after arrival was less than 10 minutes for 338 (33.3%) and less than an hour

187 for 839 (82.6%). Appointments were not needed to receive the vaccine. Finding a vaccination site  
188 was described as ‘very easy’ by 853 (84.2%), it was ‘very easy’ to get to the vaccination center for  
189 889 (87.7%), it was ‘very easy’ to financially afford transportation to the site for 877 (86.5%) and  
190 ‘very easy’ to find a vaccination site with convenient hours for 786 (77.5%) participants. Among  
191 the participants 106 (10.5%) indicated that they had to arrange for childcare, 207 (20.4%) had to  
192 take time off from paid work and 112 (11%) earned less money because they were not working  
193 and receiving the vaccine.

194

## 195 **Vaccine confidence**

196 When asked “When the COVID-19 vaccines first became available, what was your view towards  
197 COVID-19 vaccines?”, 477(47%) had ‘very negative views’ (Figure 1) and 198 (19.5%) had  
198 ‘somewhat negative’ views. Women were more likely than men (OR 1.51 (95% CI: 1.16,1.97,  
199  $p=0.002$ )) and young adults were more likely than youth (OR 1.37 (95%CI: 1.01, 1.86,  $p=0.043$ ))  
200 to have ‘very negative’ or ‘somewhat negative’ views towards COVID-19 vaccines (Table 3).

201

202 **Figure 1. Attitudes towards COVID-19 vaccine and Major concerns.** Participants were  
203 asked “When vaccines first became available, what was your view towards COVID-19  
204 vaccines?” and “It is common for people to be hesitant or unsure about getting  
205 vaccinated. Did you ever have concerns about getting the COVID-19 vaccine?”. Women  
206 had more negative views when vaccines were first available, more major concerns and  
207 concerns about side effects (\*  $p<0.05$ ; \*\*  $p<0.001$ )

208

209

210 **Table 3.** Factors associated with having a Very negative or somewhat negative view towards COVID-19 vaccines when they first became  
 211 available.

Variable	Category	Frequency (N,%)	Univariable		Multiple variables	
			OR (95% CI)	p-value	OR (95% CI)	p-value
Gender	Male	508 (50.0%)	1			
	Female	508 (50.0%)	1.573 (1.209, 2.045)	0.001	1.508 (1.156,1.967)	0.002
Age (y)	18-25	368 (36.2%)	1			
	26-39	409 (40.3%)	1.446 (1.069, 1.957)	0.017	1.371 (1.01, 1.862)	0.043
	≥40	239 (23.5%)	0.931 (0.665, 1.304)	0.679	0.869 (0.617, 1.223)	0.42
Education	Primary*	89 (8.8%)	1			
	Lower secondary	735 (72.4%)	1.179 (0.747, 1.861)	0.481		
	Higher Secondary	117 (11.5%)	1.326 (0.741, 2.374)	0.342		
	Tertiary	74 (7.3%)	1.026 (0.541, 1.945)	0.938		
Economic status	High	172 (16.9%)	1			
	Middle	598 (58.9%)	0.885 (0.618, 1.270)	0.508		
	Low	246 (24.2%)	1.122 (0.738, 1.707)	0.590		
Personal Covid Experience	No	428 (42.1%)	1			
	Yes	588 (57.9%)	0.669 (0.514, 0.870)	0.003	0.693 (0.53, 0.905)	0.007
HIV status	Negative	126 (12.4%)	1			
	Positive	890 (87.6%)	1.054 (0.708, 1.569)	0.795		
Internet use in last 30 days	No	420 (41.4%)	1			
	Yes	594 (58.6%)	0.773 (0.594, 1.006)	0.056		

212

213

214

215 A third of participants (32.6%) had major concerns about receiving the COVID-19 vaccine (Figure  
216 1). Gender, age and HIV status were associated with differences in major concerns. Women were  
217 more likely than men (OR 1.5 (95%CI: 1.15, 1.95),  $p=0.003$ ) to have major concerns (Table 4).  
218 Young adults (OR 1.52 (95% CI: 1.11, 2.09,  $p=0.009$ ) and older adults (OR 2.46 (95%CI: 1.74, 3.49,  
219  $p<0.001$ ) were more likely than youth (Table 4). Similarly, people living with HIV (PLWH) were  
220 almost twice as likely as those without HIV (OR 1.72 (95%CI: 1.18, 2.52,  $p=0.005$ ) to have major  
221 concerns about COVID-19 vaccines (Table 4). Individuals who knew someone who became  
222 seriously ill or died because of COVID-19 were less likely to have negative views (OR 0.69 (95%CI:  
223 0.53-0.91,  $p=0.007$ )) or major concerns (OR 0.69 (95%CI: 0.52-0.91,  $p=0.009$ )) compared to those  
224 who did not (Tables 3 and 4).  
225

226 **Table 4.** Major concerns about COVID-19 vaccine, Immediate side effects and Long-term health effects

Variable	Category	Frequency	Major Concerns		Immediate Side Effects		Long term Health Effect	
			OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value
Gender	Male	508	1		1		1	
	Female	508	1.5 (1.151, 1.953)	0.003*	1.342 (1.044, 1.725)	0.022*	1.416 (1.106, 1.812)	0.006*
Age (y)	18-25	368	1		1		1	
	26-39	409	1.522 (1.111, 2.085)	0.009*	1.48 (1.109, 1.975)	0.008*	1.608 (1.211, 2.135)	0.001*
	≥40	239	2.462 (1.737, 3.489)	<0.001*	1.055 (0.76, 1.465)	0.749	1.142 (0.824, 1.582)	0.426
Education	Primary	89	1		1		1	
	Lower secondary	735	0.698 (0.444, 1.098)	0.12	0.949 (0.603, 1.491)	0.819	1.172 (0.754, 1.821)	0.48
	Higher Secondary	117	0.742 (0.418, 1.319)	0.309	0.773 (0.441, 1.355)	0.369	1.219 (0.702, 2.117)	0.482
	Tertiary	74	0.994 (0.529, 1.870)	0.986	0.586 (0.313, 1.094)	0.093	1.317(0.709, 2.443)	0.383
Economic status	High	172	1		1		1	
	Middle	598	0.846 (0.59, 1.215)	0.365	1.075 (0.709, 1.560)	0.803	1.28 (0.866, 1.891)	0.215
	Low	246	1.195 (0.795, 1.796)	0.393	0.905 (0.642, 1.278)	0.572	1.016 (0.723, 1.427)	0.926
Personal Covid Experience	No	428	1		1		1	
	Yes	588	0.633 (0.482, 0.830)	0.001*	0.852 (0.661, 1.097)	0.215	0.688 (0.536, 0.884)	0.003*
HIV status	Negative	126	1		1		1	
	Positive	890	1.723 (1.179, 2.519)	0.005*	1.558 (1.047, 2.23)	0.029*	1.527 (1.044, 2.233)	0.029*
Internet use in last 30 days	No	420	1		1		1	
	Yes	594	1.036 (0.794, 1.362)	0.796	0.778 (0.604, 1.003)	0.053	1.158 (0.902, 1.488)	0.25

227

228

229 Immediate health concerns were a concern for 602 (59.3%) and long-term health effects for 520,  
230 (51.2%) (Figure 1). Young adults compared to youth (OR 1.48 (95%CI: 1.11, 1.98),  $p=0.008$ ) and  
231 PLWH (OR 1.56 (95%CI: 1.05-2.23,  $p=0.029$ ) compared to those without were more likely to  
232 express concerns about immediate side effects (Table 4). Long-term health effects were a  
233 particular concern for women compared to men, and young adults compared with youth (Table  
234 4). Those with personal knowledge of someone who was seriously ill or died from COVID-19 were  
235 less likely to indicate concerns about long-term health effects (OR 0.69 (95% CI: 0.54, 0.88,  
236  $p=0.003$ ) (Table 4).

237

238 The concern that ‘the vaccine has not been tested enough’ was expressed by 223 (21.9%), that  
239 the ‘vaccine was still new’ by 190 (18.7%) and 167 (16.4%) indicated that they did ‘not see a need  
240 for a vaccine’. Among the respondents, 293 (28.8%) chose ‘other’ for their concerns. The 293  
241 participants’ concerns focused on fear of death, infertility, health effects of vaccination,  
242 interaction with medications and comorbid conditions and interference with pregnancy and  
243 breastfeeding as well as conspiracy theories (Table 5).

244

245 Perceived vaccine safety was high with 728 (71.5%) participants strongly agreeing with the  
246 statement “In general COVID-19 vaccines are safe” (Figure 2). The odds of strongly agreeing that  
247 vaccines are safe decreased with education and internet use (Suppl Table 1). PLWH had higher  
248 odds of perceiving vaccines as safe compared to those without HIV (OR 1.71 (95%CI: 1.07, 2.74,  
249  $p=0.025$ ) (S1 Table). Although most respondents felt that the Sinovac/Sinopharm vaccine was  
250 either very safe (500 (49.2) or somewhat safe (175 (17.2%)), 311 (30.6%) indicated that they did  
251 not know if the vaccine that had received was safe.

252

253 **Table 5.** Summary of primary themes arising among the concerns expressed by study participants who listed concerns as “other”

Concern	Frequency (N=293)	Example statements and thematic areas regarding “Other concerns”
Prevailing conspiracy theories	27 (9.22%)	Feared vaccine was to depopulate Some doctors from affected countries spoke negatively about vaccines. It’s a created disease to wipe out people, dosage for Africans may be deadly Feared some foreign agent instead of the vaccine being injected into him “I think the whites want to depopulate Africans”
Death	75 (25.6%)	Feared from hearsay that vaccines would kill after a certain time Feared death and becoming a "Zombie" after vaccination Feared dying soon after vaccination I am afraid that i will not survive for 2 years after receiving the vaccine
Drug-Drug interactions and/or comorbid conditions	21 (7.17%)	Feared negative interactions between vaccine and underlying diabetes issue Won't it affect my BP? Feared contraindications between TB medication he was taking and vaccine
Fear	7 (2.39%)	Was afraid of the COVID 19 test that is done before vacation;
Effect on Fertility	21 (7.17%)	The vaccine causes infertility
Health Effect of vaccination	43 (14.68%)	“Someone in Bulawayo got vaccinated and experienced necrosis” Feared fainting or stroke due to vaccination, too many people at site Husband was saying no-one in his house gets vaccinated because he has family members who "got sick" after vaccination Feared that vaccine would distort body parts Blindness Blood clotting
HIV infection and/or co-interaction with ART	10 (3.41%)	Fear since I am HIV positive Did not understand the whole vaccination issue, was afraid of vaccination during ART
Injection site pain/swelling, fear of needles	16 (5.46%)	Fear of needles
Lack of trust or understanding of vaccine/manufacturer	26 (8.87%)	Was not trusting the vaccine Feared the coronavirus being injected into him instead of actual vaccine Concerned about manufacturers of the vaccine, that it came from China Feared that the vaccine was fake
Convenience of vaccination	11 (3.75%)	“Social [media] was saying bad things so we were afraid to come, it’s also taking too long in the queue, 1 nurse dealing with too many people” The vaccine site a bit far from home

		Identification documents were not close to him, so he couldn't get vaccinated
No need for vaccine/Did not want vaccine	2 (0.68%)	
Pregnant or Breastfeeding concerns/interactions	27 (9.22%)	Was pregnant so feared for baby I was pregnant when it started so was afraid to affect baby Effects of vaccine on pregnant wife Breast milk may dry off I was pregnant so was told I can't
Social impact	1 (0.34%)	Fear that people will gossip that am vaccinated
Worse Covid disease and concern of virus in vaccine	6 (2.05%)	You get covid Feared being injected by the virus itself whilst they pose it as a "vaccine" Feared the coronavirus being injected into him instead of actual vaccine

254

255

256

257 Perceived vaccine effectiveness was high with 699 (68.8%) participants strongly agreeing with the  
258 statement “I am confident that COVID-19 vaccines are effective in preventing the disease” (Figure  
259 2). The odds that one perceived vaccine to be effective in preventing disease decreased with  
260 increasing education and with internet use (S2 Table). PLWH compared to those without HIV (OR  
261 1.68 (95%CI: 1.07, 2.64) and those with a personal experience with COVID-19 compared to those  
262 without (OR 1.47 (95%CI: 1.12, 1.95,  $p=0.006$ ) had higher odds to strongly agree that COVID-19  
263 vaccines were effective in preventing disease (S2 Table)

264

265 **Figure 2. Perceived safety, effectiveness, and Trust in regulatory authorities.** Participants were  
266 asked “In general COVID-19 vaccines are safe”; “I am confident that COVID-19 vaccines are  
267 effective in preventing the disease” “I am confident that my country’s regulatory process  
268 approved the COVID-19 vaccine only when it was shown to be safe”.  
269

270 Perceived confidence in national regulatory processes was high with 728 (71.7%) strongly  
271 agreeing with the statement “I am confident that my country’s regulatory process approved the  
272 COVID-19 vaccine only when it was shown to be safe” (Figure 2). Increasing levels of education  
273 and internet use were associated with lower odds of strongly agreeing with the statement (S3  
274 Table). Participants with a personal experience with COVID-19 (OR 1.37 (95%CI: 1.03, 1.82),  
275  $p=0.028$ ) were more likely to be confident in national regulatory processes. Similarly, PLWH were  
276 more likely than those without HIV (OR 1.79 (95%CI: 1.11, 2.89),  $p=0.017$ ) to strongly agree with  
277 the statement (S3 Table).

278

279 Internet users consistently had lower perceived confidence in vaccine safety (OR 0.72 (95%CI:  
280 0.55, 0.95),  $p=0.02$ ), lower perceived confidence in vaccine effectiveness (OR 0.61 (95%CI: 0.47,  
281 0.50,  $p<0.001$ ) and lower perceived confidence in regulatory processes (OR 0.64 (95%CI: 0.48,  
282 0.85,  $p=0.002$ ) than those that had not used the internet in the last 30-days (S1-3 Table).

283

## 284 **Key Influencers**

285 Normative behavior can be a key motivator of vaccine uptake. The influence of others was  
286 important with 684 (67.3%) participants indicating that they strongly agreed with the statement  
287 “I came to get vaccinated because people important to me encouraged me to be vaccinated”. In  
288 addition, 702 (69.1%) of respondents strongly agreed with the statement “I came to get  
289 vaccinated today because people important to me got a COVID-19 vaccine” (Figure 3a). For 561  
290 (55.2%) participants family members were the key influencers. Religious leaders (98, (9.7%)),  
291 community leaders (56, (5.5%)), healthcare workers (133, (13.1%)) and co-workers (137 (13.5%))  
292 were less commonly listed as key influencers (figure 3b).

293

294 **Figure 3 Social influence. (a)** Participants indicated if they agreed with the statements: “I came to  
295 get vaccinated because people important to me encouraged me to be vaccinated” and “I came  
296 to get vaccinated today because people important to me got a COVID-19 vaccine” **(b)** Participant  
297 responses when asked “Which of the following help to convince you to get vaccinated, if any?”  
298

299 The reason for getting vaccinated today was to ‘protect my health’ for 862 (84.8%), to ‘protect  
300 the health of my family’ for 590 (58.1%), ‘to protect health of the people in the community’ for  
301 552 (54.3%) and ‘to get back to work or school’ for 451 (44.7%) (Suppl Fig. 7). When asked the  
302 *single* most important reason for getting vaccinated today the top two most important reasons  
303 were ‘To protect my health’ for 716 (70.4%) participants, and to ‘get back to work or school’ for  
304 152 (14.9%) (Figure 4). Among PLWH, protection of the health of the family (68.3% vs. 56.6%,  
305  $p<0.001$ ), and the health of the community (65.1% vs 52.8%,  $p<0.001$ ) were more frequently cited  
306 as reasons for vaccination compared to those without HIV infection. Resumption of social  
307 activities (2.6%), travel (2.9%) and ‘because others encouraged me to’ (2.3%) were the single  
308 most important reason for a very small number of participants (Figure 4).

309

310 **Figure 4. Reasons for presenting for vaccination today among late adopters of vaccination.**  
311 Participants were asked “Why did you get vaccinated today?”. Multiple responses were allowed  
312 (green). The subsequent follow up question was “What is the most important reason you got  
313 vaccinate today?”, a single response was allowed.  
314

## 315 **Sources of Information**

316 We asked the question ‘In the past 30 days, who have you received information from about  
317 COVID-19?’. Friend or family were the most common sources of information for 790, (77.8%),  
318 Ministry of Health for 773 (76.1%), local clinic for 596 (58.7%), religious leaders for 463 (45.6%),  
319 and the World Health Organization (WHO) for 467 (46%) (Figure 5). When asked the top 3 sources  
320 of *trusted* information about COVID-19 vaccines the primary sources were the Ministry of Health  
321 (79.7%), WHO (50.8%), local clinic (35%), local health authorities (31.1%), and friends or family  
322 (22%) (Figure5). The WHO was a more important source of information for men than women  
323 (50.4% vs. 41.5%,  $p<0.05$ ), whereas women more frequently listed their local clinic (52.2% vs.  
324 65.2%,  $p<0.0001$ ) and religious leaders (56.3% and 34.8%,  $p<0.0001$ ) among their top 3 trusted  
325 sources for information. Doctors and other health professions were in the top 3 trusted sources  
326 for 16.6% and 21.9% respectively, and alternative health providers for 4.4%.

327

328 **Figure 5. Sources and Trusted sources of information.** Participants were asked “In the past 30  
329 days, who have you received information from about COVID-19?” multiple responses were  
330 allowed (Green). Participants were subsequently asked “What are your top 3 sources of trusted  
331 information about COVID-19 vaccines?” (Red - only 3 responses allowed)  
332

333 We assessed the use of media as an information source by asking ‘In the past 30 days, where have  
334 you obtained information about COVID-19 vaccines?’. The radio (86.5%), television (76.7%),  
335 WhatsApp (62.2%) and Facebook (36.9%) were the primary media sources of information (Figure  
336 6). Radio use had high penetration and more likely to be a source for young adults compared with  
337 youth (OR 1.85 (95%CI 1.2-2.84),  $p=0.005$ ) (S4 Table). Although television had high penetration  
338 as an information source, its use tracked with education. The odds of receiving your information

339 from television were twice as high in those with lower secondary (OR 2.22 (95%CI 1.39-3.56),  
340  $p=0.001$ ) and higher secondary education (OR 2.72 (95%CI 1.35-5.48),  $p=0.005$ ) than those with  
341 primary education only (S5 Table). Social media primarily WhatsApp and Facebook as a source of  
342 information tracked strongly with age and education. Older adults had much lower odds of  
343 obtaining information from WhatsApp (OR 0.41 (95% CI 0.3-0.58),  $p<0.001$ ) (S6 Table) or  
344 Facebook (OR 0.3 (95% CI (0.2-0.45),  $p<0.001$ ) compared to youth (S7 Table). Similarly, for those  
345 with secondary and tertiary education compared to those with primary education (S6 Table).

346

347 **Figure 6. Traditional and social media sources of information.** Participants were asked “In the past  
348 30 days, where have you obtained information about COVID-19 vaccines?” and were allowed to  
349 select all that applied.

## 350 **Discussion**

351 The WHO has set an ambitious goal for COVID-19 vaccination anticipating that over 70% of  
352 populations globally will be vaccinated by the end of 2022(9). However, vaccine hesitancy is  
353 threatening that goal. The Strategic Advisory Group of Experts (SAGE) on immunization has  
354 defined vaccine hesitancy as a behavior influenced by convenience, confidence and complacency  
355 towards vaccines(11). Removing practical barriers to vaccination has strengthened various  
356 vaccination programs(15-17). Convenience was not a barrier in this study with most participants  
357 indicating that the sites were accessible and the service efficient. This may not be the case for  
358 most African populations particularly those in rural settings. Improving access is important. In this  
359 cohort, we were able to assess individual factors that may influence vaccine uptake when access  
360 barriers are minimized.

361

362 Vaccine confidence based on perceptions of safety, effectiveness and trust in regulatory  
363 processes can influence vaccine uptake. Perceptions of COVID-19 vaccines when they first came  
364 out were largely negative in this cohort, likely contributing to the ‘wait and see’ approach of

365 participants. Female gender and increasing age were more likely to be associated with negative  
366 perceptions. Gender inequities to vaccination are increasingly recognized as a major risk for  
367 successfully achieving full COVID-19 vaccination coverage with several studies suggesting that  
368 vaccine hesitancy may be higher in women(18-20). The same was observed in this cohort, with  
369 concerns focused primarily on vaccine safety. Unfortunately, up to a third of participants did not  
370 know if the vaccine that they received was safe. Communication strategies to enhance vaccine  
371 coverage will need to be gender specific and focused on information around the safety of vaccines  
372 in general and particular vaccines. The lack of consistent communication on vaccine safety in  
373 pregnancy, and ongoing social media misinformation about fertility may be important drivers of  
374 delayed vaccine uptake among women in this cohort who were concerned about effects on  
375 pregnancy, breast feeding and fertility (21, 22).

376

377 Enhancing COVID-19 vaccination uptake among PLWH especially in countries such as Zimbabwe  
378 with high HIV seroprevalence (23) will be important. People living with HIV may be at increased  
379 risk of hospitalization and death from COVID-19 particularly those that are viremic or have low  
380 CD4 counts (24, 25). In addition, immunocompromised individuals, which include people living  
381 with uncontrolled HIV infection may be an important source for ongoing SARS-CoV-2  
382 evolution(26). Within this study cohort, PLWH were almost twice as likely to have major concerns  
383 about COVID-19 vaccines and side effects than those without HIV. They were concerned about  
384 the impact on their health as well as vaccine-drug interactions with their antiretroviral therapy  
385 (ART). Vaccination rates among PLWH across different geographics are not fully understood with  
386 some studies suggesting that they may at best be like the general population(27, 28). However,  
387 vaccination coverage targets for PLWH will likely need to be higher than those for the non-  
388 immunocompromised population, particularly in settings where many people are not on ART and  
389 with high proportions of individuals with advanced HIV disease (29). Interestingly PLWH were

390 more likely to perceive vaccines as safe and effective and trust government regulatory processes.

391 This may be because PLWH on chronic therapy interact with the healthcare system often and

392 have come to trust in and rely on the services.

393

394 Perceptions of safety, effectiveness and trust in regulatory authorities also tracked significantly

395 with education and income status. Those with higher education and better income resources

396 were less likely to perceive the vaccines as effective or trust in regulatory processes. This may be

397 an important trend to watch closely as the more educated and higher income individuals are

398 often key influencers in African families and communities. Ensuring that we design

399 communication strategies that effectively target these groups will be important, particularly as

400 their access of social media-based information and disinformation is also significantly higher. In

401 this study we observed that social influence was a key factor in the motivation to engage in

402 vaccination. The descriptive norms i.e., beliefs about what others are doing regarding the

403 behavior were important motivators. The encouragement of others and the vaccination

404 behaviors of ‘people important to them’ influenced this cohort of late adopters to seek

405 vaccination. Family members were the most important influencers. Similarly, personal experience

406 in knowing someone who was seriously ill or died from COVID-19 also had a significant impact on

407 attitudes towards vaccines. Other key influencers were religious leaders and local clinics

408 particularly for women. Local nurse-led clinics are generally free in Zimbabwe and more

409 accessible than other clinics with other health providers such as medical doctors (30).

410

411 This pandemic has shown the importance of media and communications in guiding vaccine

412 uptake. Social media and the anti-vax movement are global and have become an important driver

413 of vaccine hesitancy(22, 31). Politics and trust in governments have been important in driving

414 vaccine uptake in various parts of the world(32). Although levels of trust in government may be

415 low in many countries, we found in this study that trust in government as a source of information  
416 on health and specifically COVID-19 was very high. Most participants cited the Ministry of Health  
417 as top trusted sources of information. Building and maintaining that trust in Health Ministries and  
418 regulatory processes will be critical in ensuring the success of COVID-19 and other vaccination  
419 programs.

420

421 Traditional media – radio and television were the main media sources of information. Internet  
422 based media sources were less commonly cited as major sources with only 41% of the cohort  
423 using the internet over the last 30 days. Television and radio are largely state controlled providing  
424 the authorities with an opportunity to disseminate accurate information on the safety and  
425 effectiveness of vaccines. However social media particularly WhatsApp is growing in importance  
426 and was an important source of information particularly for youth, and those with a higher  
427 economic status and more education. Communication strategies to enhance vaccine uptake  
428 should use both traditional and social media platforms but must be targeted by gender, age on  
429 each medium to be most effective.

430

431 The study provides valuable insights into late adopters of vaccination in an African setting one  
432 year after the national COVID-19 vaccination program began. Because we studied those that  
433 made the decision to be vaccinated, this research does not provide insights into those that are  
434 continuing to ‘wait and see’. Although our understanding of those that are still on the sidelines of  
435 vaccination is not yet enhanced that insights generated from this cohort will enable us to start to  
436 effectively target the ‘wait and see’ population.

437

438 The study also focused on an urban population where access was not an issue. Further  
439 understanding of barriers, motivations, and attitudes among rural populations in Africa will be

440 important. An important limitation is that our survey was not designed to evaluate complacency  
441 or hesitancy in-depth. We observed that as many as 16.4% of participants indicated that they ‘Do  
442 not see need for vaccine’. Complacency has been described as a major barrier in Africa and may  
443 become increasingly important as milder variants of SARS-CoV-2 emerge and seroprevalence  
444 from natural infection increases(33). We also did not specifically survey healthcare workers who  
445 in some settings may be key drivers of vaccine hesitancy. In sharing this data with healthcare  
446 workers many indicated that their own personal knowledge about vaccines was limited, and they  
447 would have appreciated further training and vaccine knowledge reinforcement. The impact of  
448 healthcare worker hesitancy on program success is critical and needs to be studied and  
449 addressed(34, 35).

450

451 The study data highlights the need for consistent and targeted information that is gender and age  
452 specific and targeted to subpopulations such as PLWH. Information must be delivered by trusted  
453 sources such as the Ministry of Health via traditional media platforms such as radio and television  
454 that are heavily accessed and can be used to address misinformation delivered on social media.  
455 The vaccination encounter should equip friends and family with accurate information on specific  
456 vaccines and side effects so they can act as informed social influencers for their family and friends.  
457 These individuals can be key ambassadors for vaccination within their social network. In addition,  
458 educating religious leaders who have influence over their congregations and are key sources of  
459 information, particularly among women, will be important. Vaccine hesitancy can only be tackled  
460 effectively by taking on a targeted approach to health communications that builds trust within  
461 communities using trusted communicators.

462

## 463 **Acknowledgements**

464 The study would like to acknowledge all members of the study team. Mrs Norest Beta, Mr Taddy

465 Mwarumba, Mr Edward Makaha, Mr John Musvibe, Ms Ruvimbo Chigumbu, Mr Jaffta

466 Chikwonoworo, Ms Vinie Kouamou and all the supporting and administrative staff at Charles

467 River Medical Group.

468

469

470


471 **References**


472

- 473 1. Organization WH. WHO Coronavirus (COVID-19) Dashboard.  
474 <https://covid19.who.int/>; WHO; 2022.
- 475 2. Organization WH. COVID-19 vaccine tracker and landscape.  
476 [https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-](https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines)  
477 [vaccines](https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines); WHO; 2022.
- 478 3. Organization WH. COVID-19 Vaccines.  
479 [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines2022)  
480 [vaccines2022](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines2022).
- 481 4. Wouters OJ, Shadlen KC, Salcher-Konrad M, Pollard AJ, Larson HJ,  
482 Teerawattananon Y, et al. Challenges in ensuring global access to COVID-19 vaccines:  
483 production, affordability, allocation, and deployment. *Lancet*. 2021;397(10278):1023-  
484 34.
- 485 5. Organizaton WH. Ten threats to global health in 2019:  
486 <https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019>; 2019 [
- 487 6. de Figueiredo A, Simas C, Karafillakis E, Paterson P, Larson HJ. Mapping  
488 global trends in vaccine confidence and investigating barriers to vaccine uptake: a large-  
489 scale retrospective temporal modelling study. *Lancet*. 2020;396(10255):898-908.
- 490 7. Solis Arce JS, Warren SS, Meriggi NF, Scacco A, McMurry N, Voors M, et al.  
491 COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries. *Nat*  
492 *Med*. 2021;27(8):1385-94.
- 493 8. Organizaton WH. COVID-19 Vaccination bulletin:  
494 <https://www.afro.who.int/health-topics/coronavirus-covid-19/vaccines/monthly-bulletin>;  
495 2022 [
- 496 9. Organization WH. Achieving 70% COVID-19 Immunization Coverage by Mid-  
497 2022. [https://www.who.int/news/item/23-12-2021-achieving-70-covid-19-](https://www.who.int/news/item/23-12-2021-achieving-70-covid-19-immunization-coverage-by-mid-2022#:~:text=%5B4%5D%20These%20targets%20were%20then,population%20covera)  
498 [immunization-coverage-by-mid-](https://www.who.int/news/item/23-12-2021-achieving-70-covid-19-immunization-coverage-by-mid-2022#:~:text=%5B4%5D%20These%20targets%20were%20then,population%20covera)  
499 [2022#:~:text=%5B4%5D%20These%20targets%20were%20then,population%20covera](https://www.who.int/news/item/23-12-2021-achieving-70-covid-19-immunization-coverage-by-mid-2022#:~:text=%5B4%5D%20These%20targets%20were%20then,population%20covera)  
500 [ge%20by%20mid%2D2022.2021](https://www.who.int/news/item/23-12-2021-achieving-70-covid-19-immunization-coverage-by-mid-2022#:~:text=%5B4%5D%20These%20targets%20were%20then,population%20covera).
- 501 10. Anjorin AA, Odetokun IA, Abioye AI, Elnadi H, Umoren MV, Damaris BF, et  
502 al. Will Africans take COVID-19 vaccination? *PLoS One*. 2021;16(12):e0260575.
- 503 11. Organization WH. Report of the SAGE Working Group on Vaccine Hesitancy.  
504 [http://www.who.int/immunization/sage/meetings/2014/october/1\\_Report\\_WORKING](http://www.who.int/immunization/sage/meetings/2014/october/1_Report_WORKING_GROUP_vaccine_hesitancy_final.pdf.2014)  
505 [GROUP\\_vaccine\\_hesitancy\\_final.pdf.2014](http://www.who.int/immunization/sage/meetings/2014/october/1_Report_WORKING_GROUP_vaccine_hesitancy_final.pdf.2014).
- 506 12. Montano DE KD. Theory of Reasoned Action, Theory of Planned Behavior, and  
507 the Integrated Behavioral Model. In: Glanz K RB, Viswanath K, editor. *Health*  
508 *Behavior: Theory, Research, and Practice*. 5 ed2015. p. 95-124.
- 509 13. Rosenstock IM, Strecher VJ, Becker MH. Social learning theory and the Health  
510 Belief Model. *Health Educ Q*. 1988;15(2):175-83.
- 511 14. Larson HJ, de Figueiredo A, Xiaohong Z, Schulz WS, Verger P, Johnston IG, et  
512 al. The State of Vaccine Confidence 2016: Global Insights Through a 67-Country  
513 Survey. *EBioMedicine*. 2016;12:295-301.
- 514 15. Briss PA, Rodewald LE, Hinman AR, Shefer AM, Strikas RA, Bernier RR, et al.  
515 Reviews of evidence regarding interventions to improve vaccination coverage in  
516 children, adolescents, and adults. The Task Force on Community Preventive Services.  
517 *Am J Prev Med*. 2000;18(1 Suppl):97-140.

- 518 16. Kirkdale CL, Nebout G, Megerlin F, Thornley T. Benefits of pharmacist-led flu  
519 vaccination services in community pharmacy. *Ann Pharm Fr.* 2017;75(1):3-8.
- 520 17. Omer SB, Benjamin RM, Brewer NT, Bottenheim AM, Callaghan T, Caplan A,  
521 et al. Promoting COVID-19 vaccine acceptance: recommendations from the Lancet  
522 Commission on Vaccine Refusal, Acceptance, and Demand in the USA. *Lancet.*  
523 2021;398(10317):2186-92.
- 524 18. Robertson E, Reeve KS, Niedzwiedz CL, Moore J, Blake M, Green M, et al.  
525 Predictors of COVID-19 vaccine hesitancy in the UK household longitudinal study.  
526 *Brain Behav Immun.* 2021;94:41-50.
- 527 19. Detoc M, Bruel S, Frappe P, Tardy B, Botelho-Nevers E, Gagneux-Brunon A.  
528 Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated  
529 against COVID-19 in France during the pandemic. *Vaccine.* 2020;38(45):7002-6.
- 530 20. Sypsa V, Roussos S, Engeli V, Paraskevis D, Tsiodras S, Hatzakis A. Trends in  
531 COVID-19 Vaccination Intent, Determinants and Reasons for Vaccine Hesitancy:  
532 Results from Repeated Cross-Sectional Surveys in the Adult General Population of  
533 Greece during November 2020-June 2021. *Vaccines (Basel).* 2022;10(3).
- 534 21. Murewanhema G, Dzinamarira T, Herrera H, Musuka G. COVID-19 vaccination  
535 for pregnant women in Zimbabwe: A public health challenge that needs an urgent  
536 discourse. *Public Health Pract (Oxf).* 2021;2:100200.
- 537 22. Germani F, Biller-Andorno N. The anti-vaccination infodemic on social media:  
538 A behavioral analysis. *PLoS One.* 2021;16(3):e0247642.
- 539 23. ZIMPHIA. Zimbabwe Population Based HIV Impact Assessment.  
540 <https://phia.icap.columbia.edu2020>.
- 541 24. Yang X, Sun J, Patel RC, Zhang J, Guo S, Zheng Q, et al. Associations between  
542 HIV infection and clinical spectrum of COVID-19: a population level analysis based on  
543 US National COVID Cohort Collaborative (N3C) data. *Lancet HIV.* 2021;8(11):e690-  
544 e700.
- 545 25. Nomah DK, Reyes-Uruena J, Diaz Y, Moreno S, Aceiton J, Bruguera A, et al.  
546 Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2  
547 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective  
548 cohort study. *Lancet HIV.* 2021;8(11):e701-e10.
- 549 26. Corey L, Beyrer C, Cohen MS, Michael NL, Bedford T, Rolland M. SARS-  
550 CoV-2 Variants in Patients with Immunosuppression. *N Engl J Med.* 2021;385(6):562-  
551 6.
- 552 27. Fulda ES, Fitch KV, Overton ET, Zanni MV, Aberg JA, Currier JS, et al.  
553 COVID-19 Vaccination Rates in a Global HIV Cohort. *J Infect Dis.* 2022;225(4):603-7.
- 554 28. Bogart LM, Ojikutu BO, Tyagi K, Klein DJ, Mutchler MG, Dong L, et al.  
555 COVID-19 Related Medical Mistrust, Health Impacts, and Potential Vaccine Hesitancy  
556 Among Black Americans Living With HIV. *J Acquir Immune Defic Syndr.*  
557 2021;86(2):200-7.
- 558 29. Organization WH. Guidelines for managing advanced HIV disease and rapid  
559 initiation of antiretroviral therapy  
560 <https://www.who.int/publications/i/item/9789241550062>: WHO; 2017.
- 561 30. Newman PA, Logie CH, Lacombe-Duncan A, Baiden P, Tepjan S, Rubincam C,  
562 et al. Parents' uptake of human papillomavirus vaccines for their children: a systematic  
563 review and meta-analysis of observational studies. *BMJ Open.* 2018;8(4):e019206.
- 564 31. Wilson SL, Wiysonge C. Social media and vaccine hesitancy. *BMJ Glob Health.*  
565 2020;5(10).

- 566 32. Collaborators C-NP. Pandemic preparedness and COVID-19: an exploratory  
567 analysis of infection and fatality rates, and contextual factors associated with  
568 preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021. *The Lancet*. 2022.
- 569 33. Abu EK, Oloruntoba R, Osuagwu UL, Bhattarai D, Miner CA, Goson PC, et al.  
570 Risk perception of COVID-19 among sub-Sahara Africans: a web-based comparative  
571 survey of local and diaspora residents. *BMC Public Health*. 2021;21(1):1562.
- 572 34. Mohammed R, Nguse TM, Habte BM, Fentie AM, Gebretekle GB. COVID-19  
573 vaccine hesitancy among Ethiopian healthcare workers. *PLoS One*.  
574 2021;16(12):e0261125.
- 575 35. Wiysonge CS, Alobwede SM, de Marie CKP, Kidzeru EB, Lumngwena EN,  
576 Cooper S, et al. COVID-19 vaccine acceptance and hesitancy among healthcare workers  
577 in South Africa. *Expert Rev Vaccines*. 2022;21(4):549-59.  
578  
579






- I dont know
- Strongly disagree
- Prefer not to answer
- Somewhat disagree
- Neutral
- Somewhat agree
- Strongly Agree

People important to me got the vaccine themselves

People important to me encouraged me



Number of Participants

Strongly Agree    Somewhat agree    Neutral    Somewhat disagree    Strongly disagree

